Maury Raycroft
Stock Analyst at Jefferies
(0.97)
# 2,671
Out of 4,479 analysts
38
Total ratings
26.19%
Success rate
-15.05%
Average return
Main Sectors:
Top Industries:
24 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CALT Calliditas Therapeutics AB (publ) | Downgrades: Hold | $58 → $39 | $38.75 | +0.65% | 2 | May 28, 2024 | |
| PRME Prime Medicine | Assumes: Buy | $23 → $15 | $5.28 | +184.09% | 1 | May 7, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $22 → $39 | $26.27 | +48.46% | 2 | Mar 22, 2024 | |
| CUE Cue Biopharma | Initiates: Buy | $6 | $1.08 | +455.56% | 1 | Mar 13, 2024 | |
| CRBP Corbus Pharmaceuticals Holdings | Upgrades: Buy | $4 → $46 | $48.01 | -4.19% | 1 | Mar 6, 2024 | |
| MGX Metagenomi | Initiates: Buy | $23 | $4.23 | +443.74% | 1 | Mar 5, 2024 | |
| TPST Tempest Therapeutics | Initiates: Buy | $15 | $2.12 | +607.55% | 1 | Feb 8, 2024 | |
| BCRX BioCryst Pharmaceuticals | Upgrades: Buy | $11 | $6.55 | +67.94% | 3 | Aug 4, 2023 | |
| ALLK Allakos | Upgrades: Buy | $6 → $9 | $0.84 | +970.66% | 2 | May 12, 2023 | |
| CMPX Compass Therapeutics | Initiates: Buy | $8 | $0.88 | +809.09% | 1 | Jan 31, 2023 | |
| VERA Vera Therapeutics | Downgrades: Hold | $32 → $6 | $34.93 | -82.82% | 2 | Jan 4, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $92 → $75 | $25.22 | +197.38% | 2 | Nov 29, 2022 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $218 → $232 | $247.61 | -6.30% | 1 | Oct 3, 2022 | |
| RZLT Rezolute | Initiates: Buy | $11 | $4.21 | +161.28% | 1 | Sep 12, 2022 | |
| TYRA Tyra Biosciences | Upgrades: Buy | $31 → $27 | $16.70 | +61.68% | 3 | Mar 8, 2022 | |
| BYSI BeyondSpring | Downgrades: Hold | n/a | $2.36 | - | 2 | Dec 2, 2021 | |
| CELC Celcuity | Initiates: Buy | n/a | $16.19 | - | 1 | Sep 7, 2021 | |
| ASLN ASLAN Pharmaceuticals | Initiates: Buy | n/a | $0.28 | - | 1 | Jul 9, 2021 | |
| VALN Valneva SE | Initiates: Buy | n/a | $7.25 | - | 1 | Jun 1, 2021 | |
| SLDB Solid Biosciences | Initiates: Buy | n/a | $5.96 | - | 1 | May 27, 2021 | |
| CRSP CRISPR Therapeutics AG | Upgrades: Buy | n/a | $53.12 | - | 1 | Apr 21, 2021 | |
| BDTX Black Diamond Therapeutics | Initiates: Buy | n/a | $4.21 | - | 1 | Feb 24, 2020 | |
| AFMD Affimed | Upgrades: Buy | $18 → $40 | $5.16 | +675.95% | 5 | Aug 28, 2018 | |
| NTLA Intellia Therapeutics | Maintains: Buy | n/a | $22.15 | - | 1 | Nov 1, 2017 |
Calliditas Therapeutics AB (publ)
May 28, 2024
Downgrades: Hold
Price Target: $58 → $39
Current: $38.75
Upside: +0.65%
Prime Medicine
May 7, 2024
Assumes: Buy
Price Target: $23 → $15
Current: $5.28
Upside: +184.09%
Dianthus Therapeutics
Mar 22, 2024
Maintains: Buy
Price Target: $22 → $39
Current: $26.27
Upside: +48.46%
Cue Biopharma
Mar 13, 2024
Initiates: Buy
Price Target: $6
Current: $1.08
Upside: +455.56%
Corbus Pharmaceuticals Holdings
Mar 6, 2024
Upgrades: Buy
Price Target: $4 → $46
Current: $48.01
Upside: -4.19%
Metagenomi
Mar 5, 2024
Initiates: Buy
Price Target: $23
Current: $4.23
Upside: +443.74%
Tempest Therapeutics
Feb 8, 2024
Initiates: Buy
Price Target: $15
Current: $2.12
Upside: +607.55%
BioCryst Pharmaceuticals
Aug 4, 2023
Upgrades: Buy
Price Target: $11
Current: $6.55
Upside: +67.94%
Allakos
May 12, 2023
Upgrades: Buy
Price Target: $6 → $9
Current: $0.84
Upside: +970.66%
Compass Therapeutics
Jan 31, 2023
Initiates: Buy
Price Target: $8
Current: $0.88
Upside: +809.09%
Vera Therapeutics
Jan 4, 2023
Downgrades: Hold
Price Target: $32 → $6
Current: $34.93
Upside: -82.82%
Arrowhead Pharmaceuticals
Nov 29, 2022
Maintains: Buy
Price Target: $92 → $75
Current: $25.22
Upside: +197.38%
Alnylam Pharmaceuticals
Oct 3, 2022
Maintains: Buy
Price Target: $218 → $232
Current: $247.61
Upside: -6.30%
Rezolute
Sep 12, 2022
Initiates: Buy
Price Target: $11
Current: $4.21
Upside: +161.28%
Tyra Biosciences
Mar 8, 2022
Upgrades: Buy
Price Target: $31 → $27
Current: $16.70
Upside: +61.68%
BeyondSpring
Dec 2, 2021
Downgrades: Hold
Price Target: n/a
Current: $2.36
Upside: -
Celcuity
Sep 7, 2021
Initiates: Buy
Price Target: n/a
Current: $16.19
Upside: -
ASLAN Pharmaceuticals
Jul 9, 2021
Initiates: Buy
Price Target: n/a
Current: $0.28
Upside: -
Valneva SE
Jun 1, 2021
Initiates: Buy
Price Target: n/a
Current: $7.25
Upside: -
Solid Biosciences
May 27, 2021
Initiates: Buy
Price Target: n/a
Current: $5.96
Upside: -
CRISPR Therapeutics AG
Apr 21, 2021
Upgrades: Buy
Price Target: n/a
Current: $53.12
Upside: -
Black Diamond Therapeutics
Feb 24, 2020
Initiates: Buy
Price Target: n/a
Current: $4.21
Upside: -
Affimed
Aug 28, 2018
Upgrades: Buy
Price Target: $18 → $40
Current: $5.16
Upside: +675.95%
Intellia Therapeutics
Nov 1, 2017
Maintains: Buy
Price Target: n/a
Current: $22.15
Upside: -